Paper Details

  1. Home
  2. Paper Details

Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study.

Author: AmadoriD, ArmandJ P, GamucciT, HerrmannR, MonfardiniS, NeriB, Netter-PinonJ, NowrousianM R, OberhoffC, PetryK U, RebmannU, Tubiana-MathieuN, VoigtmannR, ZwierzinaH

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study discusses the challenges of treating chemotherapy-induced anemia and the potential benefits of recombinant human erythropoietin (rhEPO) as an alternative to blood transfusions.
Paper Details　
Original Abstract of the Article :
Anemia is a common side effect of anticancer chemotherapy. Blood transfusion, previously the only available treatment for chemotherapy-induced anemia, may result in some clinical or subclinical adverse effects in the recipients. Recombinant human erythropoietin (rhEPO) provides a new treatment modal...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1023/a:1008296622469

データ提供：米国国立医学図書館（NLM）

Recombinant Human Erythropoietin: A New Approach to Chemotherapy-Induced Anemia

Chemotherapy, a powerful weapon in the fight against cancer, can sometimes have unwanted side effects, such as anemia. This study explores the use of recombinant human erythropoietin (rhEPO) in treating chemotherapy-induced anemia. Researchers conducted a randomized, controlled study to evaluate the effectiveness of rhEPO in preventing transfusion requirement associated with solid tumors. The study found that rhEPO effectively improved anemia and reduced the need for blood transfusions in patients undergoing chemotherapy, offering a new therapeutic option for this common side effect.

rhEPO: A Beacon of Hope for Chemotherapy-Induced Anemia

This research highlights the potential of rhEPO in treating chemotherapy-induced anemia. Like a refreshing oasis in the desert, rhEPO can help restore the body’s red blood cell count and reduce the need for blood transfusions. These findings offer a valuable alternative for patients experiencing this common side effect of chemotherapy.

Improving Patient Comfort and Quality of Life

The study’s findings suggest that rhEPO can help alleviate the discomfort and inconvenience associated with chemotherapy-induced anemia, improving patient comfort and quality of life. It’s like finding a cool breeze in the midst of a desert storm, bringing relief and hope. The research offers a new perspective on managing the side effects of chemotherapy and improving patient care.

Dr.Camel's Conclusion

This study provides compelling evidence for the effectiveness of rhEPO in treating chemotherapy-induced anemia. It’s like discovering a hidden wellspring of hope in the desert of cancer treatment. The findings offer a valuable new therapeutic option for patients experiencing this common side effect, improving their comfort and quality of life.

Date :
  1. Date Completed 1998-07-23
  2. Date Revised 2019-05-12
Further Info :

Pubmed ID

9602258

DOI: Digital Object Identifier

10.1023/a:1008296622469

Related Literature

Article Analysis
・Effective treatment of anemia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.